Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Medicinova Inc (MNOV)

Medicinova Inc (MNOV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 76,518
  • Shares Outstanding, K 49,050
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,040 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 0.48
  • Price/Sales 287.14
  • Price/Cash Flow N/A
  • Price/Book 1.62

Options Overview Details

View History
  • Implied Volatility 221.78% (-5.84%)
  • Historical Volatility 120.75%
  • IV Percentile 38%
  • IV Rank 16.97%
  • IV High 874.01% on 05/15/25
  • IV Low 88.50% on 12/18/24
  • Expected Move (DTE 10) 0.0425 (2.81%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 719
  • Open Int (30-Day) 946
  • Expected Range 1.4675 to 1.5525

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4000 +7.86%
on 11/21/25
1.6300 -7.36%
on 11/12/25
+0.0900 (+6.34%)
since 11/07/25
3-Month
1.1680 +29.28%
on 10/30/25
1.9600 -22.96%
on 10/31/25
+0.2500 (+19.84%)
since 09/08/25
52-Week
1.1300 +33.63%
on 04/07/25
2.3700 -36.29%
on 12/09/24
-0.8300 (-35.47%)
since 12/06/24

Most Recent Stories

More News
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.5100 (-3.21%)
Message from the CEO to MediciNova Shareholders

LA JOLLA, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, Following the recent publication in the Journal of Atherosclerosis and Thrombosis , I would like to provide additional...

MNOV : 1.5100 (-3.21%)
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.5100 (-3.21%)
MediciNova: Q3 Earnings Snapshot

MediciNova: Q3 Earnings Snapshot

MNOV : 1.5100 (-3.21%)
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.5100 (-3.21%)
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.5100 (-3.21%)
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

LA JOLLA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.5100 (-3.21%)
MediciNova to Present at the LD Micro Main Event XIX Investor Conference

LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.5100 (-3.21%)
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)

LA JOLLA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.5100 (-3.21%)
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND

LA JOLLA, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.5100 (-3.21%)

Business Summary

MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanesepharmaceutical companies,...

See More

Key Turning Points

3rd Resistance Point 1.6400
2nd Resistance Point 1.6100
1st Resistance Point 1.5600
Last Price 1.5100
1st Support Level 1.4800
2nd Support Level 1.4500
3rd Support Level 1.4000

See More

52-Week High 2.3700
Fibonacci 61.8% 1.8963
Fibonacci 50% 1.7500
Fibonacci 38.2% 1.6037
Last Price 1.5100
52-Week Low 1.1300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar